• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Tuesday 04/24/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

ATTBF

  • 10:34 AM

    VANCOUVER, British Columbia, March 13, 2018 /PRNewswire/ — Abattis Bioceuticals Corp. (the “Company” or “Abattis “) (CSE: ATT) (OTC: ATTBF) is pleased to announce it has entered into a non-binding letter of intent (the “LOI“) with Canadian Artesian Ice Ltd. (“Canadian Artesian“) to provide Canadian Artesian with, among other things, THC- and pesticide-free cannabidiol (“CBD“) isolate, research and development services, nanoencapsulation and nanoemulsification services, analytical and regulatory services and access to Abattis’s distribution and marketing channels to support the development, scalability and commercialization of

    Read more
  • 3:32 PM

    LEXINGTON, MA— XBIO, (Marketwired – February 12, 2016) – Xenetic Biosciences, Inc. (OTCQB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics (“Xenetic”) announced today that OPKO Health, Inc. (NYSE: OPK) has acquired an approximate 6.3% interest in Xenetic. Commenting on the investment in Xenetic, Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., stated, “Xenetic has many novel technologies that address unmet needs in various orphan cancer indications, and we believe the science

    Read more
  • 2:00 PM

    LOS ANGELES, CA– OTCQB, ENDV, (Marketwired – Sep 16, 2015) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a biotechnology company developing non-invasive, bioelectronic products with anti-inflammatory properties designed to promote regeneration in damaged tissue and organs, announced today the commencement of the Company’s patent licensing program. The first of several patent applications filed with the United States Patent and Trademark Office is currently available for licensing to potential corporate partners. Initially, the technology being offered by the

    Read more
  • 12:58 PM

    Aug 03, 2015 OTC Disclosure & News Service, SVON, OTCQB -Sevion Therapeutics, Inc. (“Sevion” or the “Company”) (OTCQB:SVON) today announced that on July 27, 2015 the Company closed a private placement with certain accredited investors (the “Offering”) whereby the Company sold units consisting of shares common stock or convertible preferred stock of the Company and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $6,548,963. Each share of the convertible preferred stock is initially convertible into

    Read more
  • 7:07 PM

    LEXINGTON, Mass., July 08, 2015 (GLOBE NEWSWIRE) — Xenetic Biosciences, Inc. (“Xenetic” or the “Company”) (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has completed a $3,000,000 bridge note financing. The financing was concluded with OJSC Pharmsynthez (“Pharmsynthez”), a collaborative partner of Xenetic and an affiliate of Xenetic’s largest shareholder SynBio LLC (“Synbio”) and was arranged directly between the managements of Xenetic and Pharmsynthez on a commission free basis.

    Read more
  • 2:56 PM

    97% tumour inhibition demonstrated in colorectal cancer models ADELAIDE, Australia, June 15, 2015 /PRNewswire/ — Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, announced today that it filed a patent application covering the use of BNC105 in combination with immune checkpoint inhibitors for the treatment of cancer. This new patent is based on important preclinical findings regarding the synergistic effects in preclinical models

    Read more
Public Wire Banner